Published in Diabetes on July 22, 2008
Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol (2010) 2.52
Abnormal angiogenesis in diabetic nephropathy. Diabetes (2009) 1.53
Modulation of notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy. Diabetes (2010) 1.21
Vegfa protects the glomerular microvasculature in diabetes. Diabetes (2012) 1.16
Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia (2011) 1.15
Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem (2011) 1.05
VEGF and podocytes in diabetic nephropathy. Semin Nephrol (2012) 1.02
Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol (2013) 0.99
Angiogenesis and chronic kidney disease. Fibrogenesis Tissue Repair (2010) 0.99
Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig (2014) 0.98
Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J Am Soc Nephrol (2013) 0.98
Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes (2009) 0.96
Albuminuria is associated with too few glomeruli and too much testosterone. Kidney Int (2013) 0.93
Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes. Diabetes (2013) 0.93
Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice. Am J Physiol Renal Physiol (2010) 0.92
Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol (2014) 0.91
Endothelial factors and diabetic nephropathy. Diabetes Care (2011) 0.91
Renal endothelial dysfunction in diabetic nephropathy. Cardiovasc Hematol Disord Drug Targets (2014) 0.90
Glomerular VEGF resistance induced by PKCδ/SHP-1 activation and contribution to diabetic nephropathy. FASEB J (2012) 0.87
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy. Am J Physiol Renal Physiol (2015) 0.83
Signal transduction in podocytes--spotlight on receptor tyrosine kinases. Nat Rev Nephrol (2014) 0.82
Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy. J Diabetes Res (2013) 0.81
Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside. Pediatr Res (2011) 0.79
Relevance of VEGF and nephrin expression in glomerular diseases. J Signal Transduct (2011) 0.78
Crosstalk in glomerular injury and repair. Curr Opin Nephrol Hypertens (2015) 0.78
The vasculature in diabetic nephropathy: all tied up? J Am Soc Nephrol (2013) 0.75
Impaired Albumin Uptake and Processing Promote Albuminuria in OVE26 Diabetic Mice. J Diabetes Res (2016) 0.75
Diabetes-Induced Reactive Oxygen Species: Mechanism of Their Generation and Role in Renal Injury. J Diabetes Res (2017) 0.75
Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes. Biomed Res Int (2013) 0.75
Mechanism of kidney injury caused by bevacizumab in rats. Int J Clin Exp Pathol (2014) 0.75
PACSIN2 accelerates nephrin trafficking and is up-regulated in diabetic kidney disease. FASEB J (2017) 0.75
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem (1994) 6.18
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A (1993) 5.02
Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med (2006) 4.26
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A (2000) 3.48
Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem (2003) 3.36
Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun (1996) 3.33
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes (1999) 2.16
Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol (2006) 2.10
Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol (2007) 2.06
Inducible podocyte-specific gene expression in transgenic mice. J Am Soc Nephrol (2003) 1.87
Role of the VEGF--a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol (2007) 1.80
Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol (2001) 1.75
Susceptibility of glomerular filtration rate estimations to variations in creatinine methodology: a study in older patients. Ann Clin Biochem (2005) 1.74
Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem (1996) 1.73
Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes (2002) 1.67
Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int (2006) 1.59
Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens (2001) 1.54
Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. J Am Soc Nephrol (2000) 1.52
Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol (2006) 1.51
Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol (2002) 1.41
Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int (2005) 1.41
Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol (2006) 1.38
Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation (2002) 1.27
Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol (2004) 1.23
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia (2001) 1.21
Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes. Diabetes (2004) 1.19
New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol (2004) 1.17
Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J Atheroscler Thromb (2006) 1.17
Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res (2004) 1.14
Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest (2001) 1.11
Nephrin in experimental glomerular disease. Kidney Int (2000) 1.09
Differential expression of nephrin according to glomerular size in early diabetic kidney disease. J Am Soc Nephrol (2007) 1.02
MMP-mediated events in diabetes. Ann N Y Acad Sci (1999) 0.98
Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol (2000) 0.95
Cloning and expression of the rat nephrin homolog. Am J Pathol (1999) 0.90
Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension (2005) 0.90
VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun (2005) 0.90
Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int (1999) 0.84
Podocyte changes upon induction of albuminuria in Thy-1.1 transgenic mice. Nephrol Dial Transplant (2003) 0.84
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med (2011) 11.11
Cohesins functionally associate with CTCF on mammalian chromosome arms. Cell (2008) 7.80
Establishment of histone h3 methylation on the inactive X chromosome requires transient recruitment of Eed-Enx1 polycomb group complexes. Dev Cell (2003) 7.11
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
Detection of thyroid dysfunction in early pregnancy: Universal screening or targeted high-risk case finding? J Clin Endocrinol Metab (2006) 3.37
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet (2008) 2.89
Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet (2010) 2.55
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet (2008) 2.49
The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension (2009) 2.47
Avosentan for overt diabetic nephropathy. J Am Soc Nephrol (2010) 2.32
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol (2007) 2.06
Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet (2007) 2.05
Post-embryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype. FASEB J (2005) 2.03
Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A (2007) 1.82
GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics (2006) 1.70
Angiopoietin-1 therapy enhances fibrosis and inflammation following folic acid-induced acute renal injury. Kidney Int (2008) 1.70
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension (2008) 1.60
Prevalence and concomitants of glucose intolerance in European obese children and adolescents. Diabetes Care (2003) 1.58
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes (2011) 1.53
IGF-I induces vascular endothelial growth factor in human mesangial cells via a Src-dependent mechanism. Kidney Int (2003) 1.43
Deregulation of the serum- and glucocorticoid-inducible kinase SGK1 in the endometrium causes reproductive failure. Nat Med (2011) 1.41
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.41
Aortic pulse wave velocity and albuminuria in patients with type 2 diabetes. J Am Soc Nephrol (2005) 1.31
GAA repeat instability in Friedreich ataxia YAC transgenic mice. Genomics (2004) 1.26
eNOS deficiency predisposes podocytes to injury in diabetes. J Am Soc Nephrol (2012) 1.26
Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Am J Pathol (2011) 1.17
Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration. Kidney Int Suppl (2005) 1.16
Health promotion for adolescents in primary care: randomised controlled trial. BMJ (2002) 1.15
Microalbuminuria and cardiovascular risk. Am J Hypertens (2004) 1.14
Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol (2006) 1.13
The role of PC-1 and ACE genes in diabetic nephropathy in type 1 diabetic patients: evidence for a polygenic control of kidney disease progression. Nephrol Dial Transplant (2002) 1.08
Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol (2008) 1.07
Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol (2005) 1.04
Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J Am Soc Nephrol (2007) 1.02
Sonic hedgehog signalling inhibits palatogenesis and arrests tooth development in a mouse model of the nevoid basal cell carcinoma syndrome. Dev Biol (2009) 1.02
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol (2011) 1.01
Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications (2002) 0.99
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension (2003) 0.98
Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J Am Soc Nephrol (2013) 0.98
Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrol Dial Transplant (2009) 0.98
A role for TRPV1 in influencing the onset of cardiovascular disease in obesity. Hypertension (2012) 0.98
Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptivity in women with recurrent pregnancy loss. PLoS One (2012) 0.98
A missense mutation in the murine Opa3 gene models human Costeff syndrome. Brain (2008) 0.96
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2009) 0.94
Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J Am Soc Nephrol (2010) 0.93
Albuminuria is associated with too few glomeruli and too much testosterone. Kidney Int (2013) 0.93
Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care (2006) 0.92
Endothelial factors and diabetic nephropathy. Diabetes Care (2011) 0.91
Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs (2010) 0.90
Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance. PLoS One (2012) 0.90
Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol (2010) 0.90
Mapping and functional analysis of regulatory sequences in the mouse lambda5-VpreB1 domain. Mol Immunol (2005) 0.89
Developmental stalling and organ-autonomous regulation of morphogenesis. Proc Natl Acad Sci U S A (2011) 0.89
Fluorescence-based sensing of glucose using engineered glucose/galactose-binding protein: a comparison of fluorescence resonance energy transfer and environmentally sensitive dye labelling strategies. Biochem Biophys Res Commun (2007) 0.89
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. Clin J Am Soc Nephrol (2013) 0.89
An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension (2014) 0.89
Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care (2010) 0.88
Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum (2011) 0.88
Impaired glucose tolerance in obese children and adolescents. N Engl J Med (2002) 0.87
Glucose induces increases in levels of the transcriptional repressor Id2 via the hexosamine pathway. Am J Physiol Endocrinol Metab (2005) 0.86
HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes. Diabetes Care (2007) 0.85
Six-year prognosis of diabetic patients with coronary artery disease. Eur J Clin Invest (2011) 0.85
VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment? Metabolism (2012) 0.85
A reappraisal of evidence for probabilistic models of allelic exclusion. Proc Natl Acad Sci U S A (2008) 0.85
Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Int J Cardiol (2010) 0.84
Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol (2014) 0.83
The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst (2005) 0.83
The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. J Hypertens (2011) 0.83
N-3 PUFA increase bioavailability and function of endothelial progenitor cells. Food Funct (2014) 0.83
Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. J Am Soc Nephrol (2005) 0.81
Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study. Thromb Res (2006) 0.81
Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. Am J Nephrol (2010) 0.81
Synchronous cryptogenic liver cirrhosis and idiopathic pulmonary fibrosis: a clue to telomere involvement. Hepatology (2012) 0.81
Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes. Clin J Am Soc Nephrol (2012) 0.81
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. BMC Nephrol (2014) 0.81
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc (2014) 0.80
ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant (2008) 0.80